Clinical trial Recruiting at 1 site Interventional Ages Any age to 80

Autologous Bone Marrow Cells With Wharton Gel Exosomes for Liver Cirrhosis

Official title: A New Regenerative Medicine Protocol Using Autologous Bone Marrow Mononuclear Cells With Growth Factors to Treat Liver Cirrhosis

Run by Global Stem Cell Center, Baghdad · NCT07374185 · Data updated 2026-11-12

Doctors are testing whether using a patient’s own bone marrow cells with Wharton gel exosomes can help the liver repair itself in people with liver cirrhosis.

More Liver Cirrhosis trials

Quick facts

Study typeInterventional
AgesAny age to 80 Years
SexAll
Enrollment10 (estimated)
SponsorGlobal Stem Cell Center, Baghdad
Industry-sponsored
Locations1 site (Baghdad, Iraq)
StatusRecruiting
StartedFebruary 20, 2026
Main results expectedDecember 20, 2026
Study endsDecember 20, 2026
Registry record updatedSeptember 15, 2026
Trial IDNCT07374185 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults under 80 with liver cirrhosis who do not have active cancer, sepsis, or pregnancy.

Probably not a fit

Patients with active life-threatening conditions, including malignancy or severe sepsis, may not benefit from this therapy.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study uses autologous bone marrow–derived mononuclear cells collected from the patient’s iliac crest, processed to concentrate viable cells, and combined with a small amount of Wharton gel exosomes before intravenous administration. The approach aims to support liver tissue repair in adults with cirrhosis who do not have active cancer or other life-threatening conditions. Enrollment includes adults under 80 with cirrhosis, excluding those with active malignancy, severe sepsis, or pregnancy. The study is led by Global Stem Cell Center in Baghdad and conducted at Capital Private Hospital in Iraq.

Why it matters

Potential benefit: If successful, participants may experience improved liver function or slowed progression of cirrhosis.

How similar studies have gone: Previous mesenchymal stem cell approaches for liver disease show potential, but this exact combination with Wharton gel exosomes is novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria: any patient with liver cirrhosis , less than 80 years of age -

Exclusion Criteria:

1. active malignancy.
2. severe sepsis.
3. pregnancy. -

Where it's running

  • Capital Private Hospital Alrabee Street
    Baghdad, Iraq, Iraq
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Browse more
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.